Cholesterol

Plant-based Milk Market to Reach $7.3 Billion Globally by 2032 at 10.3% CAGR: Allied Market Research

Retrieved on: 
Thursday, January 11, 2024
Allergy, Table, Cholesterol, Supermarket, COVID-19, PDF, Hain Celestial Group, Health, Lactose intolerance, Growth

WILMINGTON, Del., Jan. 11, 2024 /PRNewswire/ -- Allied Market Research has recently published a report, titled, "Plant-based Milk Market by Milk Type (Almond, Soy, Rice, Oat, Coconut, Others), by Distribution Channel (Online, Supermarket, Convenience Stores), by End-User (Retail/Household, Foodservices Industry, Food and Beverage Industry): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global plant-based milk market generated $2.8 billion in 2022, and is anticipated to generate $7.3 billion by 2032, witnessing a CAGR of 10.3% from 2023 to 2032.

Key Points: 
  • Increasing interest in health and wellness during the pandemic drove a surge in demand for plant-based milk products.
  • Lockdowns and disruptions in the supply chain caused delays in production and distribution, temporarily impacting the market growth.
  • The rising popularity of online shopping and home deliveries during the pandemic boosted plant-based milk producers' adaptation to e-commerce, strengthening direct consumer reach.
  • The North America region dominated the global plant-based milk market in 2022, holding a major share of 33.3%.

HealthSense® High-Fiber Wheat Flour Earns American Heart Association's Heart-Check Certification

Retrieved on: 
Wednesday, January 10, 2024
American Heart Association, Taste, Health, American Journal, Risk, Disease, UCLA Health, UCLA, Medicine, Cholesterol, Appetite, Dietary supplement

QUINCY, Mass., Jan. 10, 2024 /PRNewswire/ -- Bay State Milling Company's HealthSense® High-Fiber Wheat Flour, the only refined flour in the U.S. made from non-GMO high-amylose wheat, has received the prestigious Heart-Check Certification from the American Heart Association. HealthSense flour joins a select number of products that meet the American Heart Association's rigorous criteria for foods and food ingredients that support heart health as part of a nutritious diet.

Key Points: 
  • QUINCY, Mass., Jan. 10, 2024 /PRNewswire/ -- Bay State Milling Company's HealthSense® High-Fiber Wheat Flour , the only refined flour in the U.S. made from non-GMO high-amylose wheat, has received the prestigious Heart-Check Certification from the American Heart Association.
  • HealthSense flour joins a select number of products that meet the American Heart Association's rigorous criteria for foods and food ingredients that support heart health as part of a nutritious diet.
  • "The American Heart Association's Heart-Check mark is the most-recognized symbol of heart-healthy products in the United States.
  • According to the American Heart Association, while many factors affect heart disease, diets low in saturated fat and cholesterol may help reduce the risk of this disease.

New Research Shows Potential Benefits of Swapping Some Meat Intake with Walnuts

Retrieved on: 
Tuesday, January 9, 2024
Well, Mortality, BMC Medicine, Alpha-Linolenic acid, Patient, Meal, Research, ALA, Meta-analysis, Collection, Diet, Nut, Meat, Magnesium, Bias, NHANES, Risk, National Health, Medicine, Eating, Quality, Type 2 diabetes, Grain boundary strengthening, Vegetable, RDN, Copper, Cholesterol, Doctor of Public Health, Cardiovascular disease, Dietary fiber, Red meat, Dietary supplement

FOLSOM, Calif., Jan. 9, 2024 /PRNewswire/ -- Food trends are constantly evolving and one of the most exciting trends for 2024 is focused on putting the "plant" back in "plant-based".1

Key Points: 
  • Walnuts also have the ability to take on the texture and consistency of ground meat, allowing for seamless integration into a variety of recipes.
  • The researchers used data from the 2015 - 2018 National Health and Nutrition Examination Survey (NHANES), to model the nutrient intake of the US population with and without walnuts.
  • Specifically, 0.5, 1, 1.5 and 2 ounces of walnuts per day replaced 1, 2, 3 and 4 ounces of meat.
  • Important to note: all age and gender groups maintained vitamin B12 intake above the recommended daily allowance when replacing 2–3 ounces of meat with walnuts.

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Patient, Common, Medical Subject Headings, Marketing, LDL, Cholesterol, Artery, Agency, INN, Risk, Hypercholesterolemia, IIA, ATC, Moyamoya disease, Comparable, Pain, Blood, International, Diet, Coronary artery disease, Disease, Ageing, Nose, Language, Heart, Stroke, Abdomen, Red, Splenic infarction, Goal, European Medicines Agency, Thigh, Select, Cell, Chest pain, Safety, Fats, Anatomy, PCSK9, Ezetimibe, Primary, Throat, Skin, Medical device

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Hypothyroidism, INN, Woman, Progression-free survival, Nausea, Syndrome, Heart, Cancer, Inflammation, Skull, Proteinuria, Anatomy, Cell division, IIA, Diarrhea, Fatigue, ATC, Capsule, Bleeding, Pancreas, RET, VEGF, FGFR, Cerebral edema, Neoplasm, Stroke, Enzyme, Liver failure, Safety, Kidney cancer, Arthralgia, Heart failure, Patient, Urine, Medical Subject Headings, Stomatitis, Immune system, Everolimus, International, Encephalopathy, Language, Somatic symptom disorder, Blood, Mouth, Catherine Disher, Select, Medicine, Vomiting, Pembrolizumab, Cholesterol, PDGF, Kidney failure, Weight loss, Headache, KIT, Brain, Acral lentiginous melanoma, Swelling, Hypoesthesia, Splenic infarction, Confusion, European Medicines Agency, RCC, Kidney, Growth, Sunitinib, Hypercholesterolemia, Rash, Medical device

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Conscious Capital Growth Announces Business Accelerator Partnership with CHOP5 Salad Kitchen

Retrieved on: 
Thursday, January 4, 2024
Cholesterol, Ecosystem, The Wall Street Journal, Health, News, Accelerator, Growth, Gain (electronics), Intelligence, Fast food

SCOTTSDALE, Ariz., Jan. 4, 2024 /PRNewswire/ -- Conscious Capital Growth has partnered with CHOP5 Salad Kitchen , an emerging franchise concept, to provide access to its business growth platform, which includes accelerated franchise development systems, enhanced site selection expertise, and access to their ecosystem of business resources making them one of the first franchise companies to enter Conscious Capital Growth's Accelerator program.

Key Points: 
  • SCOTTSDALE, Ariz., Jan. 4, 2024 /PRNewswire/ -- Conscious Capital Growth has partnered with CHOP5 Salad Kitchen , an emerging franchise concept, to provide access to its business growth platform, which includes accelerated franchise development systems, enhanced site selection expertise, and access to their ecosystem of business resources making them one of the first franchise companies to enter Conscious Capital Growth's Accelerator program.
  • Conscious Capital Growth announces its Accelerator program with CHOP5 Salad Kitchen as the program's first brand.
  • CHOP5 Salad Kitchen, based in Columbus, OH, shows great potential for growth because of its product mix and service model.
  • Accelerator is a Conscious Capital Growth program with extensive qualification criteria.

Drugs of the future will be easier and faster to make, thanks to mRNA – after researchers work out a few remaining kinks

Retrieved on: 
Thursday, January 4, 2024
RNA, Pseudouridine, Liver, Pfizer, University of Massachusetts, Cholesterol, Protein, Phospholipid, Immune system, Infection, Drug development, Messenger, Messenger RNA, CRISPR, Vaccine, Method, Disease, Half-life, Tissue, Endosome, DNA, Heart, Nobel Prize, Program, COVID-19, Engineering, Gene, Cell, Time, Physiology, Medicine, Therapy, Uridine, DSM-IV codes, Algorithm, Orthornavirae

Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process.

Key Points: 
  • Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process.
  • But the COVID-19 mRNA vaccines brought a new approach to vaccine development that has far-reaching implications for how researchers make drugs to treat many other diseases.

Some basics of mRNA drugs

  • An mRNA drug comprises two essential components: mRNA molecules, which code for desired proteins, and the lipid molecules – such as phospholipids and cholesterol – that encapsulate them.
  • From a drug development perspective, mRNA drugs offer significant advantages over traditional drugs because they are easily programmable.
  • More importantly, different mRNA drugs produced by the same set of methods will have similar properties.
  • This predictability significantly reduces the development risks and financial costs of developing mRNA drugs.

Self vs. nonself

  • This may sound paradoxical – after all, your cells already contain large amounts of mRNAs.
  • How does your immune system distinguish between self and nonself mRNAs?
  • Therapeutic mRNAs enter cells using endosomes – sacs made of the cell’s membrane that take in materials from the cell’s environment.
  • The 2023 Nobel Prize in physiology or medicine was awarded to the scientists who made this breakthrough discovery.
  • RNA viruses also form double-stranded RNA when they replicate, and exposing cells to double-stranded RNA can lead to a strong immune response.
  • Fortuitously, for mRNA vaccines, the residual amount of double-stranded RNA can stimulate the immune system to enhance antibody responses.

Moving beyond vaccines

  • One promising example in development is using mRNA that encodes CRISPR-Cas9 gene-editing proteins to knock out genes that cause specific diseases.
  • This disease is an ideal target for mRNA-based CRISPR gene therapy because the target protein is produced by the liver.
  • Notable new developments in these areas include using computational algorithms to optimize mRNA sequences in ways that enhance their stability and engineering RNA polymerases that introduce fewer side products that may cause an immune response.
  • Further advancements have the potential to enable a new generation of safe, durable and effective mRNA therapeutics for applications beyond vaccines.


Li Li receives funding from NIH.

Drugs of the future will be easier and faster to make, thanks to mRNA − after researchers work out a few remaining kinks

Retrieved on: 
Thursday, January 4, 2024
RNA, Pseudouridine, Liver, Pfizer, University of Massachusetts, Cholesterol, Protein, Phospholipid, Immune system, Infection, Drug development, Messenger, Messenger RNA, CRISPR, Vaccine, Method, Disease, Half-life, Tissue, Endosome, DNA, Heart, Nobel Prize, Program, COVID-19, Engineering, Gene, Cell, Time, Physiology, Medicine, Therapy, Uridine, DSM-IV codes, Algorithm, Orthornavirae

Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process.

Key Points: 
  • Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process.
  • But the COVID-19 mRNA vaccines brought a new approach to vaccine development that has far-reaching implications for how researchers make drugs to treat many other diseases.

Some basics of mRNA drugs

  • An mRNA drug comprises two essential components: mRNA molecules, which code for desired proteins, and the lipid molecules – such as phospholipids and cholesterol – that encapsulate them.
  • From a drug development perspective, mRNA drugs offer significant advantages over traditional drugs because they are easily programmable.
  • More importantly, different mRNA drugs produced by the same set of methods will have similar properties.
  • This predictability significantly reduces the development risks and financial costs of developing mRNA drugs.

Self vs. nonself

  • This may sound paradoxical – after all, your cells already contain large amounts of mRNAs.
  • How does your immune system distinguish between self and nonself mRNAs?
  • Therapeutic mRNAs enter cells using endosomes – sacs made of the cell’s membrane that take in materials from the cell’s environment.
  • The 2023 Nobel Prize in physiology or medicine was awarded to the scientists who made this breakthrough discovery.
  • RNA viruses also form double-stranded RNA when they replicate, and exposing cells to double-stranded RNA can lead to a strong immune response.
  • Fortuitously, for mRNA vaccines, the residual amount of double-stranded RNA can stimulate the immune system to enhance antibody responses.

Moving beyond vaccines

  • One promising example in development is using mRNA that encodes CRISPR-Cas9 gene-editing proteins to knock out genes that cause specific diseases.
  • This disease is an ideal target for mRNA-based CRISPR gene therapy because the target protein is produced by the liver.
  • Notable new developments in these areas include using computational algorithms to optimize mRNA sequences in ways that enhance their stability and engineering RNA polymerases that introduce fewer side products that may cause an immune response.
  • Further advancements have the potential to enable a new generation of safe, durable and effective mRNA therapeutics for applications beyond vaccines.


Li Li receives funding from NIH.

MAA Sauces Infuse Home-Cooked Meals With Exotic and Authentic Indian Curry

Retrieved on: 
Thursday, January 4, 2024
Magic, MAA, Cholesterol, Nutrient, Spice, History, Oil, MSG, Fast food

FORT LAUDERDALE, Fla., Jan. 4, 2024 /PRNewswire/ -- MAA Sauces are a unique and elegant take on the Indian sauce experience. Created by Harry "Guru" Khanna, the range of revolutionary kitchen treasures comes from a rich history of Indian cuisine combined with relentless forward-thinking, entrepreneurial investment and innovation.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 4, 2024 /PRNewswire/ -- MAA Sauces are a unique and elegant take on the Indian sauce experience.
  • His reputation as an Indian chef grew, and he began to zero in on perfecting his sauces.
  • However, to truly create the greatest Indian sauce brand on the market, the ambitious entrepreneur knew he had to go further.
  • They are easy to prepare on the homefront and enable even those with minimal experience in the kitchen to enjoy a truly masterful, exotic, and authentic Indian cuisine experience.

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Retrieved on: 
Thursday, January 4, 2024
Marketing, Cholesterol, Ultragenyx, NHS England, Adolescence, Hammersmith Hospital, Diet, Ageing, Clinical trial, Trauma, Heart UK, Patient, NHS, ANGPTL3, Lipid, Pharmaceutical industry

Evkeeza is recommended within its marketing authorization as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adults and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).

Key Points: 
  • Evkeeza is recommended within its marketing authorization as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adults and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).
  • Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for this rare and debilitating condition.
  • "We are very pleased that NICE has approved the use of evinacumab within the NHS.
  • The NICE committee acknowledged that clinical trial evidence shows that Evkeeza, combined with other lipid-lowering therapies (LLTs), can lower LDL-C levels when statins and other LLTs have not reduced them enough.